

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

CIN : L51900MH1985PLC035738

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31 MARCH 2015

**PART I**

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Twelve Months ended
		31/03/2015	31/12/2014	31/03/2014	31/12/2014
		Unaudited	(Refer Note No. 5)	Unaudited	Audited
<b>1</b>	<b>Income from Operations</b>				
a)	Net Sales/Income from Operations	10,062.99	12,162.82	18,821.36	66,695.07
b)	Other Operating Income	142.53	75.31	61.98	368.20
c)	<b>Total Income from Operations</b>	<b>10,205.52</b>	<b>12,238.13</b>	<b>18,883.34</b>	<b>67,063.27</b>
<b>2</b>	<b>Expenses</b>				
a)	Cost of materials consumed	17,329.82	8,796.93	9,288.04	61,783.87
b)	Purchase of stock-in-trade	0.00	0.00	0.00	0.00
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10,548.63)	46.66	3,361.80	(15,232.62)
d)	Employee benefits expense	1,226.99	1,216.86	1,379.97	5,167.27
e)	Depreciation and amortization expense	7,049.55	8,480.34	6,388.86	27,657.43
f)	Other Expenses	881.99	932.21	1,179.53	3,852.80
g)	<b>Total Expenses</b>	<b>15,939.72</b>	<b>19,473.00</b>	<b>21,598.20</b>	<b>83,228.75</b>
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(5,734.20)</b>	<b>(7,234.87)</b>	<b>(2,714.86)</b>	<b>(16,165.48)</b>
4	Other Income	0.00	0.00	0.00	0.00
<b>5</b>	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(5,734.20)</b>	<b>(7,234.87)</b>	<b>(2,714.86)</b>	<b>(16,165.48)</b>
6	Finance Costs	7,639.36	8,759.83	12,581.10	46,950.57
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(13,373.56)</b>	<b>(15,994.70)</b>	<b>(15,295.96)</b>	<b>(63,116.05)</b>
8	Tax expense				
a)	Current	0.00	0.00	0.00	0.00
b)	Deferred	(4,339.00)	(5,189.00)	(4,963.00)	(20,478.00)
c)	Total	(4,339.00)	(5,189.00)	(4,963.00)	(20,478.00)
<b>9</b>	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(9,034.56)</b>	<b>(10,805.70)</b>	<b>(10,332.96)</b>	<b>(42,638.05)</b>
10	Extraordinary Items	0.00	0.00	0.00	0.00
<b>11</b>	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(9,034.56)</b>	<b>(10,805.70)</b>	<b>(10,332.96)</b>	<b>(42,638.05)</b>
12	Prior year adjustment	0.00	(1,932.47)	0.00	(3,132.47)
<b>13</b>	<b>Profit available for appropriation</b>	<b>(9,034.56)</b>	<b>(12,738.17)</b>	<b>(10,332.96)</b>	<b>(45,770.52)</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,720.48	2,720.48	2,678.74	2,720.48
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				101,026.03
16.i	Earnings Per Equity Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)				
a)	Basic	(3.32)	(3.97)	(3.86)	(15.67)
b)	Diluted	(2.09)	(2.50)	(2.39)	(9.85)
16.ii	Earnings Per Equity Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)				
a)	Basic	(3.32)	(4.68)	(3.86)	(16.82)
b)	Diluted	(2.09)	(2.94)	(2.39)	(10.57)



**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

CIN : L51900MH1985PLC035738

Select Information for the Quarter ended 31 March 2015

**PART II**

Sr. No.	Particulars	Three Months ended			Twelve Months ended
		31/03/2015	31/12/2014	31/03/2014	31/12/2014
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
<b>1</b>	Public Shareholding				
	- Number of Equity shares	135,545,090	135,545,090	131,861,090	135,545,090
	- Percentage of shareholding	49.82%	49.82%	49.23%	49.82%
<b>2</b>	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	Number of Equity shares	50,816,835	50,816,835	50,816,835	50,816,835
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	55.94%	55.94%	55.94%	55.94%
	Percentage of shares (as a % of the total Equity share capital of the Company)	18.68%	18.68%	18.97%	18.68%
	b) Non-encumbered				
	Number of Equity shares	40,023,300	40,023,300	40,023,300	40,023,300
	Percentage of Shares (as a % of the total Equity shareholding of promoter and promoter group)	44.06%	44.06%	44.06%	44.06%
	Percentage of shares (as a % of the total Equity share capital of the Company)	14.71%	14.71%	14.94%	14.71%

Sr. No.	Particulars	Quarter ended 31/03/2015
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	0

**Notes:**

- The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 15 May, 2015.
- The Statutory Auditors have carried out a limited review of the financial results for the quarter ended on 31 March 2015.
- The Company has Overseas Subsidiaries and there are no business operations in the subsidiary companies.
- The Figures of the previous Quarter ended on 31 December 2014 are the Balancing figures between the audited figures in respect of the full financial year ended on 31 December 2014 and published year to date figures upto the third quarter ended on 30 September 2014.
- The Company has, during the Quarter allotted 230,885,800 Unlisted 8% Redeemable Cumulative Non-Participating Non-Convertible Preference Shares carrying no Voting Rights of face value of Rs.10/- each at par.
- Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of  
**STERLING BIOTECH LIMITED**

Chetan J. Sandesara  
Joint Managing Director  
DIN - 00255671



Place : Mumbai  
Date : 15 May 2015.



Review Report to **Board of Directors of Sterling Biotech Limited**  
43, Atlanta,  
Nariman Point,  
Mumbai – 400 021.

I have reviewed the accompanying statement of unaudited financial results of **Sterling Biotech Limited** for the period ended 31<sup>st</sup> March, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by me. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. My responsibility is to issue a report on these financial statements based on my review.

I conducted my review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **H. S. Hathi & Co.**  
Chartered Accountants  
Firm Reg. No. : 103596W

  
**Hemant S. Hathi**  
Membership No. 37109  
Proprietor



Place : Mumbai  
Date : 15-05-2015